AstraZeneca Iressa NDA Update: Will Sept. 24 ODAC Review Go Forward?
Executive Summary
AstraZeneca and FDA appear close to deciding whether to proceed with the Oncologic Drugs Advisory Committee review of Iressa (gefitinib) scheduled for Sept. 24
You may also be interested in...
AstraZeneca Iressa (correction)
AstraZeneca's non-small cell lung cancer agent Iressa (gefitinib) showed no improvement in survival as add-on therapy to standard chemotherapy in the Phase III INTACT trials. "The Pink Sheet" incorrectly described the regimen in the INTACT studies (1"The Pink Sheet" Sept. 16, p. 25). The Sept. 24 FDA Oncologic Drugs Advisory Committee review of Iressa is expected to proceed as scheduled...
AstraZeneca Iressa (correction)
AstraZeneca's non-small cell lung cancer agent Iressa (gefitinib) showed no improvement in survival as add-on therapy to standard chemotherapy in the Phase III INTACT trials. "The Pink Sheet" incorrectly described the regimen in the INTACT studies (1"The Pink Sheet" Sept. 16, p. 25). The Sept. 24 FDA Oncologic Drugs Advisory Committee review of Iressa is expected to proceed as scheduled...
AstraZeneca Iressa Focus Is Sequential Therapy After INTACT Studies Fail
AstraZeneca is looking at Iressa monotherapy as an element of sequential chemotherapy regimens for solid tumors following the failure of the INTACT studies, VP-Medical Director of Oncology George Blackledge told an Aug. 19 conference call